A systematic review of the existing literature identified only 90 patients with ICI-induced DM, and observed that most patients were treated with anti-PD-1/PD-L1 monotherapy (71%) or anti-PD1/PD-L1 in combination with CTLA-4 blockade (15%), while anti-CTLA-4 alone accounted for only 3% of the patients (106). This evidence concerns the gene CD274 and diabetes mellitus.